For research use only. Not for therapeutic Use.
PMX205(CAT; I008791) is a potent and selective antagonist of the C5a receptor (CD88), offering significant anti-inflammatory effects. By inhibiting C5a activity, PMX205 modulates immune responses, as demonstrated in preclinical studies. It effectively ameliorates experimentally induced colitis, increasing anti-inflammatory cytokines IL-4 and IL-10 and preventing DSS-induced colitis. These findings highlight its potential as a therapeutic option for inflammatory bowel disease (IBD). Additionally, PMX205 reduces inflammation in murine models of allergic asthma, further emphasizing its utility in addressing immune-mediated disorders. Its targeted mechanism supports its role in advancing research within inflammation and immunology-related pharmaceutical fields.
Catalog Number | I008791 |
CAS Number | 514814-49-4 |
Synonyms | PMX205; PMX-205; PMX 205.;N-((3R,6S,9S,15S,20aS)-6-((1H-indol-3-yl)methyl)-3-(cyclohexylmethyl)-9-(3-guanidinopropyl)-1,4,7,10,16-pentaoxoicosahydropyrrolo[1,2-a][1,4,7,10,13]pentaazacyclooctadecin-15-yl)-3-phenylpropanamide |
Molecular Formula | C45H62N10O6 |
Purity | ≥95% |
Target | Complement System |
Solubility | Soluble in DMSO |
Storage | -20°C |
IUPAC Name | N-[(3S,9S,12S,15R,18S)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1H-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide |
InChI | InChI=1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2, |
InChIKey | VATFHFJULBPYLM-ILOBPARPSA-N |
SMILES | O=C([C@]([H])(CC1=CNC2=C1C=CC=C2)NC([C@@H](CC3CCCCC3)NC([C@]4(N5CCC4)[H])=O)=O)N[C@@H](CCCNC(N)=N)C(NCCC[C@@]([H])(C5=O)NC(CCC6=CC=CC=C6)=O)=O |